Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10065754 | 1.00 | ALDH1A1 (0.43) | ALDH1A1CA2EPHX1NPSR1CHRM2 | |
| SCHEMBL10972837 | 0.94 | ALDH1A1 (0.52) | ALDH1A1CA2EPHX1NPSR1CHRM2 | |
| SCHEMBL12059431 | 0.94 | ALDH1A1 (0.52) | ALDH1A1CA2EPHX1NPSR1CHRM2 | |
| SCHEMBL31362255 | 0.92 | ALDH1A1 (0.55) | ALDH1A1CA2EPHX1NPSR1CYP1A2 | |
| SCHEMBL10975960 | 0.92 | ALDH1A1 (0.55) | ALDH1A1CA2EPHX1NPSR1CYP1A2 | |
| SCHEMBL11410475 | 0.92 | ALDH1A1 (0.55) | ALDH1A1CA2EPHX1NPSR1CYP1A2 | |
| SCHEMBL10974424 | 0.92 | ALDH1A1 (0.55) | ALDH1A1CA2EPHX1NPSR1CYP1A2 | |
| SCHEMBL31362247 | 0.92 | ALDH1A1 (0.55) | ALDH1A1CA2EPHX1NPSR1CYP1A2 | |
| SCHEMBL13130046 | 0.89 | CA2 (0.47) | ALDH1A1CA2NPSR1CHRM2CHRM4 | |
| SCHEMBL8330854 | 0.87 | CA2 (0.46) | ALDH1A1CA2NPSR1CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612106-B2 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090258892-A1 | FUSED PYRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-7241792-B2 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-20070073062-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258892-A1 | FUSED PYRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ACE, ACE2, AGTR2 | ALDH1A1 794/4885CA2 1524/4885EPHX1 712/4885 |
| US-20070073062-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ACE, ACE2, AGTR2 | ALDH1A1 794/4885CA2 1524/4885EPHX1 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.